Charlotte Risager Christensen

Charlotte Risager Christensen

Auto-generated profile, based on publicly available information

Charlotte Risager Christensen

Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2025 in Science
Verified
Journal Article
Closed access
KJKristoffer Haurum Johansen
Kristoffer Haurum Johansen
DWDarian Stephan Wolff
Darian Stephan Wolff
BSBeatrice Scapolo
Beatrice Scapolo
MFMonica Fernandez-Quintero
Monica Fernandez-Quintero
CCCharlotte Risager Christensen
Charlotte Risager Christensen
Timothy P. JenkinsTimothy P. Jenkins
Timothy P. Jenkins
The recognition of intracellular antigens by CD8 + T cells through T cell receptors (TCRs) is central for adaptive immunity against infections and cancer. However, the identification of TCRs from patient material remains complex. We present a rapid de novo minibinder (miBd) design platform leveraging state-of-the-art generative models to engineer miBds targeting the cancer-associated peptide-bound major histocompatibility complex (pMHC) SLLMWITQC/HLA-A*02:01 (NY-ESO-1). Incorporating in silico cross-panning enabled computational prescreening of specificity, and molecular dynamics simulations allowed for improved predictability of in vitro success. We identified a high-affinity NY-ESO-1 binder and confirmed its structure using cryo–electron microscopy, which, when incorporated in a chimeric antigen receptor, induced killing of NY-ESO-1 + melanoma cells. We further designed and validated binders to a neoantigen pMHC complex, RVTDESILSY/HLA-A*01:01, with unknown structure, demonstrating the potential for precision immunotherapy.

3 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
KJKristoffer Haurum Johansen
Kristoffer Haurum Johansen
DWDarian Wolff
Darian Wolff
BSBeatrice Scapolo
Beatrice Scapolo
MFMonica Fernandez-Quintero
Monica Fernandez-Quintero
CCCharlotte Risager Christensen
Charlotte Risager Christensen
Timothy P. JenkinsTimothy P. Jenkins
Timothy P. Jenkins
The recognition of intracellular antigens by CD8+ T cells through T cell receptors (TCRs) is central to adaptive immunity, enabling responses against infections and cancer. The recent approval of TCR-gene-edited T cells for cancer therapy demonstrates the therapeutic advantage of using pMHC recognition to eliminate cancer. However, identification and selection of TCRs from patient material is complex and influenced by the TCR repertoire of the donors used. To overcome these limitations, we here present a rapid and robust de novo binder design platform leveraging state-of-the-art generative models, including RFdiffusion, ProteinMPNN, and AlphaFold2, to engineer minibinders (miBds) targeting the cancer-associated pMHC complex, NY-ESO-1(157-165)/HLA-A*02:01. By incorporating in silico cross-panning and molecular dynamics simulations, we enhanced specificity screening to minimise off-target interactions. We identified a miBd that exhibited high specificity for the NY-ESO-1-derived peptide SLLMWITQC in complex with HLA-A*02:01 and minimal cross-reactivity in mammalian display assays. We further demonstrate the therapeutic potential of this miBd by integrating it into a chimeric antigen receptor, as de novo Binders for Immune-mediated Killing Engagers (BIKEs). BIKE-transduced T cells selectively and effectively killed NY-ESO-1+ melanoma cells compared to non-transduced controls, demonstrating the promise of this approach in precision cancer immunotherapy. Our findings underscore the transformative potential of generative protein design for accelerating the discovery of high-specificity pMHC-targeting therapeutics. Beyond CAR-T applications, our workflow establishes a foundation for developing miBds as versatile tools, heralding a new era of precision immunotherapy.